Výsledky vyhledávání

Enhanced neutrophil activity, but not neutrophil extracellular trap markers, is found in patients with symptomatic chronic peripheral arterial disease

Autor: G Buso, E Faggin, A Bressan, S Galliazzo, F Cinetto, C Felice, M Fusaro, A Erdmann, P Pauletto, M Rattazzi, L Mazzolai

Publikováno v: European Heart Journal. 43

Background/Introduction Neutrophil degranulation and neutrophil extracellular traps (NETs) are suggested to play a role in cardiovascular (CV) disease development [1]. Human studies showed that markers of NETs, are increased in patients with severe c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc0de5d9479f6a37c1cbc66c98db63e4
https://doi.org/10.1093/eurheartj/ehac544.1979

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

Autor: G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

Publikováno v: Reumatismo, Vol 65, Iss 2, Pp 75-78 (2013)

Inflammatory bowel disease (IBD) is commonly associated with peripheral inflammatory arthritis, and it has been estimated that as many as 12% of IBD patients report these manifestations. However, rheumatoid arthritis (RA) is rarely associated with ul

Externí odkaz: https://doaj.org/article/e55118c5592a46779678e93b1ec3dfc1

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P398 Long term efficacy and safety of ABP, 501 adalimumab biosimilar in inflammatory bowel diseases: preliminary results from the ADASWITCH study

Autor: A Cingolani, C Felice, G Lombardi, F M Onidi, D Checchin, R Colucci, L Grossi, A Ferronato, C Rocchi, M Ascolani, L Binaghi, M F Dore, L Fanini, M Bulajic, G Mocci MD FRCP

Publikováno v: Journal of Crohn's and Colitis. 16:i392-i393

Background Adalimumab (ADA) biosimilars have been developed to have a much lower financial cost than ADA originator. The aim of this study was to evaluate the long term efficacy and safety of Adalimumab biosimilar ABP501 in naïve or switched Inflamm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6d61b8987360d0c8e6fab2f551258c9d
https://doi.org/10.1093/ecco-jcc/jjab232.525

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání